HbA1c News and Research

RSS

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood.

From Ortho-Clinical Diagnostics, Inc. 22 Jun 2015

Sebia’s Capillarys 3 Tera automated electrophoresis solution receives CE mark

Sebia, the world leader in capillary electrophoresis, today announces that Capillarys 3 Tera now has the CE mark for HbA1c and serum protein testing, and immunotyping. The CE mark for these tests is the first step in bringing the Capillarys 3 suite to market.

12 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston.

29 May 2015

Study explores accuracy of body weight perception and obesity in Chinese Americans

Worldwide, obesity is becoming more prevalent. According to The World Health Organization, worldwide obesity has nearly doubled since 1980, and in 2008 25% of adults aged 20 and over were overweight, and another 11% were obese. Obesity has been identified as a major source of unsustainable health costs and numerous adverse outcomes, including morbidity and mortality due to hypertension, type 2 diabetes, cardiovascular diseases and certain types of cancer.

28 May 2015

Treatment outcomes in type 1 diabetes could be improved across all age groups

In a sweeping analysis assessing the current state of diabetes treatment in the U.S., T1D Exchange researchers conclude that there remains considerable room for improving treatment outcomes in type 1 diabetes across all age groups, but especially for adolescents and young adults.

22 May 2015

Continuous glucose monitoring using real-time CGM helps better manage diabetes

Patients with insulin-dependent diabetes can better control their HbA1c value with a combination of blood glucose self-monitoring (BGSM) and continuous interstitial glucose monitoring (CGM) using a real-time measurement device (real-time CGM) than with BGSM alone without severe or serious hypoglycaemia occurring more frequently.

21 May 2015

Shiftworkers more likely to develop metabolic disorders

Shiftwork is an occupational health risk of growing significance because it is becoming more common and because of its potential influence on health outcomes, possibly increasing health differences between workers of higher vs lower socioeconomic status.

18 May 2015

AMC Health to collaborate with URAC on national telehealth standards development initiative

AMC Health, a leading provider of 'real-time' patient management solutions has announced that it will collaborate with URAC on its national telehealth standards development initiative.

5 May 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study.

1 Apr 2015

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint.

27 Mar 2015

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, and AMC Health, a privately held provider of 'real-time' patient management solutions, today announced a collaborative effort to accelerate the transformation of chronic care and population health management by significantly enhancing connectivity and care coordination for at-risk patients, specifically those with heart failure, hypertension, diabetes, asthma or COPD, in a cost-effective manner.

25 Mar 2015

PTS Diagnostics announces launch of PTS Connect Wellness Solution

PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek brand and the A1CNow family of point-of-care diagnostic products, announces the launch of the PTS Connect Wellness Solution. This secure cloud-based solution will empower health screening companies to screen more individuals faster and corporate wellness programs to improve outcomes by encouraging participants to monitor and track activity and progress online.

10 Mar 2015

Study finds correlation between tests for hemoglobin A1c using finger stick and oral blood

It is estimated that 8.1 million of the 29.1 million Americans living with diabetes are undiagnosed and many who have diabetes have poor glycemic control. Given that each year many Americans visit a dental provider but not a primary care provider, dental visits may be an opportune site for diabetes screening and monitoring glucose control for many at-risk patients.

27 Feb 2015

EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured

From EKF Diagnostics 23 Feb 2015

Study: Definitive indicator of diabetes control deceptively high in African-American children

A new study confirms the findings of two earlier LSU Health New Orleans studies that the definitive indicator of diabetes control, the HbA1c, is deceptively high in African-American children.

19 Feb 2015

Large majority of coronary patients fail to meet lifestyle, risk factor targets

The large majority of coronary patients in Europe are failing to achieve their lifestyle, risk factor and therapeutic targets as set out in the latest prevention guidelines.

17 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Study: About one-third of teens, young adults face social barriers to diabetes management

Managing type 1 diabetes is a never-ending task that requires multiple blood glucose tests, carbohydrate calculations and insulin injections or infusions. This constant effort to control the disease is daunting at any age - and it's especially challenging for teens and young adults.

2 Feb 2015